ATHM vs BATRA

The deterministic scorecard reveals a mixed financial health with a Piotroski F-Score of 6/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a full distress risk assessment. Despite attractive valuation metrics such as a low P/E of 13.07 and a Price/Book of 0.79, the company faces significant headwinds including negative earnings momentum, declining revenue growth, and a dangerously high payout ratio exceeding 100%. The stock trades below analyst target of $27.71 yet remains in a prolonged downtrend with a 5Y return of -75.8%, signaling deep market skepticism. Strong gross margins and zero debt are offset by deteriorating profitability trends and weak technical posture.

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and a missing Altman Z-Score prevents a full solvency assessment. Despite strong year-over-year earnings growth and solid operating margins, the company is unprofitable on net (negative profit margin and ROE), carries a high debt/equity ratio of 1.52, and shows poor liquidity with current and quick ratios below 1.0. Valuation metrics are stretched, with a negative forward P/E and a Price/Book of 4.80, while insider activity is decisively bearish, with recent selling by major shareholders. The stock has underperformed recently, down 13.4% over six months, and lacks analyst coverage, increasing uncertainty.